Skip to main content

Table 7 Readmissions within 90 Days of Discharge

From: Efficacy and safety of aerosol inhalation of recombinant human interferon α1b (IFNα1b) injection for noninfluenza viral pneumonia, a multicenter, randomized, double-blind, placebo-controlled trial

  

FAS

 

PPS

Item

IFN α1b Group

Control Group

IFN α1b Group

Control Group

Readmission within 90 days of discharge

5 (6.6%)

4 (4.6%)

5 (7.2%)

4 (4.9%)

No readmission within 90 days of discharge

71 (93.4%)

83 (95.4%)

64 (92.8%)

78 (95.1%)

Total (Missing)

76 (0)

87 (0)

69 (0)

82 (0)

Statistics

Fisher’s exact probability test

Fisher’s exact probability test

P

0.735

0.733